Thymosin Alpha-1 Research: Trials, Immune Data & What the Studies Show
Thymosin Alpha-1 (Tα1) is a 28-amino-acid thymus peptide. As the thymus shrinks with age, native Tα1 falls, which is why it is studied in immune-aging research. The synthetic medicine form is thymalfasin (Zadaxin). It is licensed in many countries for chronic hepatitis B and related immune-support uses. This listing is not Zadaxin and is for laboratory research only.
Thymosin Alpha-1 (Tα1) Research Context
Thymosin alpha-1 is a 28-amino-acid thymus peptide. As the thymus shrinks with age, native Tα1 falls, which is why it is studied in immune-aging research. The synthetic medicine form is thymalfasin (Zadaxin). It is licensed in many countries for chronic hepatitis B and related immune-support uses. That international dossier is the strong part of the story. This listing is not Zadaxin and is for laboratory research only.
- Innate-to-adaptive bridging: Tα1 acts at Toll-like receptors and is studied as a connector between first-line defense and T-cell immunity. Research looks at raising defense pathways during an active threat and at regulatory T cells (Tregs) that restrain excess immune activity.
- Immunosenescence: Aging-immune work examines T-cell maturation, thymic-output markers, and vaccine-response readouts when Tα1 signaling is restored in older or thymus-impaired models.
- Inflammatory-cytokine models: Studies measure pro-inflammatory signals such as IL-6 and TNF-alpha against anti-inflammatory proteins. This is immune-balance research, including autoimmune-damage models — not a treatment claim.
- Antiviral and infection research: Tα1 is documented for dendritic-cell maturation and NK-cell efficiency. That is why it appears next to standard therapy in chronic hepatitis B and C literature, with additional work in HIV and other persistent-infection models.
- Oxidative-stress models: Beyond lymphocyte counts, research reports lower reactive oxygen species and higher cell-defense enzymes such as superoxide dismutase and glutathione in tissue, astrocyte, and vessel models.
Tα1 stands out because the T-cell/TLR biology is specific and because thymalfasin is a real medicine in multiple countries. These are research findings and foreign-approval facts. They are not claims that this product restores immunity, treats infection or autoimmunity, or protects organs.
Mechanism of action
Tα1 is studied as an immune modulator rather than a simple stimulant. Research examines its role at Toll-like receptors, its influence on T-cell development, and its effects on innate and adaptive immune signalling.
The compound's interest lies in the size of its clinical dossier: more than 30 trials and over 11,000 human subjects across infection, oncology and ageing, with thymalfasin approved for use in several countries outside the United States.
The studies
Tα1 has one of the largest human evidence bases of any compound in this catalogue. Note the pattern across it: broad all-comer endpoints often fail while pre-specified subgroups show clear effects — a signal that patient selection matters more than dose in this literature.
Critical care
TESTS trial — sepsis and critical illness
Whether Thymosin Alpha-1 reduces mortality in adult sepsis.
1,106 adult sepsis patients · multicentre, double-blind, placebo-controlled · 28-day all-cause mortality primary endpoint with pre-specified subgroups
- 1,106
- Participants
- No overall reduction
- 28-day all-cause mortality
- Elderly (60+) & diabetes
- Subgroup benefit
- The largest RCT conducted on Tα1 to date, enrolling 1,106 adult sepsis patients.
- Tα1 did not decrease broad 28-day all-cause mortality across the general study population.
- Pre-specified subgroup analyses revealed a distinct survival advantage in patients over 60 and individuals with diabetes — populations with baseline immune impairment.
Safety & evidence base
Comprehensive clinical safety and efficacy review
Pooled safety and efficacy of Tα1 across its entire clinical literature.
Comprehensive narrative review · over 30 separate trials · more than 11,000 human subjects across oncology, infection and autoimmunity
- 11,000+
- Subjects reviewed
- 30+
- Trials reviewed
- Zero reported
- Major adverse toxicities
- Investigators observed uniform evidence validating Tα1's safety profile and therapeutic efficacy in oncology, severe respiratory infections including COVID-19 variants, and autoimmune disorders.
- The peptide was well tolerated with zero major adverse toxicities reported across the pooled dataset.
- This breadth of human exposure is unusual for a compound sold in the research market.
Ageing & immunity
Counteracting age-related immune decline
Whether Tα1 offsets thymic involution and immunosenescence in older populations.
Focused research on thymic involution · naive T-cell output, vaccine antibody response and inflammatory-ageing markers
- Stimulated
- Naive T-cell production
- Improved
- Vaccine antibody response
- Refnot hybrid
- Combination candidate
- Addresses thymic involution — the gradual shrinkage of the thymus gland that drives immunosenescence with age.
- Tα1 mitigated age-related immune decay by stimulating naive T-cell production and improving antibody response to vaccines.
- The work also highlighted new therapeutic combinations, including the hybrid compound Refnot, designed to slow systemic inflammatory ageing.
Oncology
Chemotherapy and immunotherapy adjuvant support
Tα1 combined with multi-modality chemotherapy and checkpoint inhibitors.
Tα1 alongside chemotherapy and modern immunotherapies including CTLA-4 and PD-1/PD-L1 inhibitors · median survival and marrow suppression endpoints
- 38.4 months
- Median survival (Tα1 first)
- 8.0 months
- Median survival (control)
- Counteracted
- Marrow suppression
- Patients receiving Tα1 prior to immunotherapy achieved a median survival time of 38.4 months versus 8.0 months in the non-Tα1 control group.
- It counteracts chemotherapy-induced bone marrow suppression, supporting treatment tolerance.
- Mechanistic work focuses on priming cell-mediated antitumour immunity ahead of CTLA-4 and PD-1/PD-L1 blockade.
Chronic viral infection
Chronic hepatitis B and C remission trials
Synthetic Tα1 (thymalfasin) versus placebo in chronic viral liver infection.
Randomised clinical trials · synthetic thymalfasin versus placebo · virological response, HBeAg seroconversion and liver enzyme normalisation
- 40.6%
- Virological response (Tα1)
- 9.4%
- Virological response (control)
- Normalised
- Liver enzymes
- Tα1 drove a 40.6% virological response rate versus 9.4% in control groups.
- It facilitated significant HBeAg seroconversion and normalised liver enzyme levels.
- These results underpin the approvals of Zadaxin (thymalfasin) for chronic hepatitis in multiple countries outside the US.
Hepatitis B & C — antiviral adjuvant trials
Whether adding Tα1 to standard antiviral therapy improves viral clearance in chronic hepatitis B and C.
Pooled meta-analysis of nearly 2,850 patients · Tα1 plus standard antivirals versus antivirals alone · virological clearance endpoints
Outcome
Adding Tα1 to standard treatments increased the number of patients who completely cleared the Hepatitis virus from their blood by 23% compared to taking standard antivirals alone. It helped kickstart the 'exhausted' immune systems of chronic patients. (Note: While highly effective, it has largely been phased out in modern medicine by newer, direct-acting antiviral pills).
- ~2,850
- Patients pooled
- +23%
- Viral clearance boost
- vs antivirals alone
- Comparison
- Pooled Phase II and Phase III data show Tα1 increased complete viral clearance by 23% when added to standard antiviral therapy.
- The effect is attributed to restoring exhausted immune responses in chronic hepatitis patients.
- Modern direct-acting antivirals have largely replaced this regimen in current clinical practice.
Oncology
Melanoma & lung cancer — immunotherapy and radiation adjuvant trials
Whether Tα1 improves response to pembrolizumab in metastatic melanoma and extends cancer-free survival after lung-cancer radiation.
Phase II melanoma trial at MD Anderson · Tα1 plus pembrolizumab versus pembrolizumab alone · plus lung-cancer radiation adjuvant work · tumour response and lymphopenia endpoints
Outcome
In the melanoma trial, adding Tα1 doubled the treatment success rate (31% tumor response versus the standard 15–18% from immunotherapy alone). In lung cancer trials, it significantly lengthened the time patients lived cancer-free. It also drastically reduced the severe drops in white blood cells (lymphopenia) caused by harsh radiation and chemo.
- 31%
- Melanoma response (Tα1 + pembro)
- 15–18%
- Melanoma response (pembro alone)
- Reduced
- Chemo/radio lymphopenia
- Tα1 plus pembrolizumab produced a 31% tumour response rate in metastatic melanoma, roughly double the rate reported with pembrolizumab alone.
- Lung-cancer adjuvant trials report longer cancer-free survival when Tα1 is added after radiation.
- Tα1 reduced severe lymphopenia caused by chemotherapy and radiotherapy, supporting treatment tolerance.
Critical care
TESTS — sepsis Phase III trial
Whether Tα1 reduces 28-day mortality in adult sepsis.
Over 1,100 adult sepsis patients across medical hubs · Tα1 twice daily for one week versus placebo · 28-day all-cause mortality primary endpoint
Outcome
It did not work as hoped for general sepsis. While smaller initial studies suggested it might reduce ICU mortality, this large-scale gold-standard trial proved that Tα1 did not lower the 28-day death rate in general adult sepsis patients.
- 1,100+
- Participants
- No mortality benefit
- Primary endpoint
- Elderly & diabetes
- Subgroup benefit
- The TESTS Phase III trial found no reduction in 28-day all-cause mortality across the broad adult sepsis population.
- Earlier smaller studies had hinted at an ICU survival benefit, but the large RCT did not confirm it.
- Pre-specified subgroups (elderly and diabetic patients) still showed a signal of benefit.
Respiratory infection
COVID-19 — cytokine-storm and T-cell recovery trials
Whether Tα1 limits disease progression and accelerates viral clearance in COVID-19.
Dozens of trials and real-world studies · thousands of COVID patients · disease progression, viral clearance and T-cell recovery endpoints
Outcome
Mixed and highly dependent on timing. For non-severe patients, Tα1 did not stop the disease from getting worse, but it did help them clear the virus out of their bodies faster, shortening their hospital stays. For severe, oxygen-dependent patients, early use helped rebuild their virus-fighting T-cells quickly. However, giving it too late to critically ill ICU patients yielded no benefit.
- Dozens
- Trials/real-world studies
- Thousands
- Patients tracked
- Timing-dependent
- Key effect
- In non-severe COVID-19, Tα1 did not prevent progression but sped up viral clearance and shortened hospitalisation.
- In severe, oxygen-dependent patients treated early, Tα1 helped rebuild virus-fighting T-cells.
- Tα1 showed no benefit when given late to critically ill ICU patients.
Vaccine response
Flu and pandemic vaccine adjuvant trials
Whether Tα1 improves antibody response to standard vaccines in immunocompromised patients.
Clinical trials in immunocompromised populations including kidney-dialysis patients · Tα1 alongside standard flu and pandemic vaccines · antibody response endpoints
Outcome
The peptide acted like a megaphone for the vaccines, prompting the patients' weak immune systems to build significantly more protective antibodies without causing any negative side effects.
- Immunocompromised
- Population
- Significantly higher
- Antibody response
- No negative effects
- Side effects
- Tα1 given alongside standard vaccines significantly increased protective antibody responses in immunocompromised patients.
- The adjuvant effect was observed in flu and pandemic vaccine trials, including kidney-dialysis cohorts.
- No negative side effects were attributed to the peptide in these studies.
Storage & handling
Thymosin Alpha-1 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake — Tα1 is a 28-amino-acid chain and vulnerable to mechanical denaturation.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.